Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Targeting the shift from m1 to m2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil.
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.
Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis.
Journal Club: Intrathecal effects of daclizumab treatment of multiple sclerosis.
Can PET imaging tell us what's the matter with the gray matter in multiple sclerosis?
Immune-related GTPase Irgm1 exacerbates experimental auto-immune encephalomyelitis by promoting the disruption of blood-brain barrier and blood-cerebrospinal fluid barrier.
Transient gadolinium leakage in natalizumab-treated multiple sclerosis.
Multiple sclerosis reactivation postfingolimod cessation: Is it IRIS?
Simvastatin inhibits interferon-gamma-induced MHC class II up-regulation in cultured astrocytes.
Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS.
Torque teno mini virus infection and multiple sclerosis.
Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions.
Genetic characterization of gliomas arising in patients with multiple sclerosis.
Active intrathecal herpes simplex virus type 1 (HSV-1) and human herpesvirus-6 (HHV-6) infection at onset of multiple sclerosis.
Caffeine and alcohol intakes have no association with risk of multiple sclerosis.
Associations of alcohol consumption with clinical and MRI measures in multiple sclerosis.
A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients.
Multiple sclerosis: The potassium channel KIR4.1-a potential autoantigen in MS.
Cross Cultural Validation of The Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.
Fingolimod-Associated Peripheral Vascular Adverse Effects.
Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.
Regulatory effects of fisetin on microglial activation.
Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial

Pages